- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
GE Capital invests in R2 Technology
R2 Technology strengthened its relationship with GE last month with the signing of an $11 million financing agreement led by GE's financing arm, GE Capital. The financing will be used for working capital purposes as R2 prepares for an initial public
R2 Technology strengthened its relationship with GE last month with the signing of an $11 million financing agreement led by GE's financing arm, GE Capital. The financing will be used for working capital purposes as R2 prepares for an initial public offering that the company plans to launch some time this year. R2 did not disclose what percentage of the Los Altos, CA, company GE Capital now owns.
R2 has developed ImageChecker M1000, a computer-aided diagnosis product for flagging suspicious areas on mammograms. The product is awaiting Food and Drug Administration approval. R2 signed an agreement with GE Medical Systems in April that gives the Milwaukee company rights to the product when sold with full-field digital mammography systems (SCAN 4/29/98). The financing deal with GE Capital was not directly related to the GEMS agreement, according to an R2 spokesperson.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
